Cyclophosphamide Enhances Glioma Virotherapy by Inhibiting Innate Immune Responses

Clinical trials are testing oncolytic viruses (OVs) as therapies for cancer. We have shown that animals that have brain tumors and are treated with a herpes simplex virus (HSV)-derived OV live significantly longer when cyclophosphamide (CPA) is preadministered. Here, we explore the mechanisms behind...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Proceedings of the National Academy of Sciences - PNAS 2006-08, Vol.103 (34), p.12873-12878
Hauptverfasser:	Fulci, Giulia, Breymann, Laura, Gianni, Davide, Kurozomi, Kazuhiko, Rhee, Sarah S., Yu, Jianhua, Kaur, Balveen, Louis, David N., Weissleder, Ralph, Caligiuri, Michael A., Chiocca, E. Antonio
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Biological Sciences Brain Neoplasms - pathology Brain Neoplasms - therapy Brain Neoplasms - virology Cancer Cell Line, Tumor Cell Proliferation Cells Clinical trials Cyclophosphamide - administration & dosage Cyclophosphamide - pharmacology Cyclophosphamide - therapeutic use Gene expression Gene therapy Glioma Glioma - immunology Glioma - pathology Glioma - therapy Glioma - virology Herpes simplex virus Immunity, Innate - drug effects Immunity, Innate - immunology Infections Interferon-gamma - metabolism Macrophages Male Natural killer cells Neoplasm Transplantation Oncology Oncolytic Virotherapy Phagocytes Pretreatment Rats Rodents Simplexvirus Simplexvirus - drug effects Simplexvirus - immunology Tumors Virion - drug effects Virus Replication - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!